Theranexus (EPA:ALTHX) | WebDisclosure

Basculer en Français

10605	Companies
225020	Keywords
153740	Articles
119079	Press releases

Home
Companies
Theranexus

PRESS RELEASE

published on 07/03/2024 at 07:30, 1 year 11 months ago

THERANEXUS, LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP WIN THE "2024 RESEARCH PACT" PROJECT FOR THE AUVERGNE-RHÔNE-ALPES REGION
Theranexus, Lyon Neuroscience Research Center, and CERMEP win research pact project 'IMASO' in Auvergne-Rhône-Alpes Region for preclinical neuroimaging in rare neurological diseases

Theranexus Neurological Diseases Research Pact Auvergne-Rhône-Alpes Region Preclinical Neuroimaging
BRIEF

published on 06/06/2024 at 07:35, 2 years ago

Theranexus et BBDF annoncent des résultats positifs à 18 mois pour Batten-1 dans une étude de phase 1/2

Theranexus Batten-1 Maladie De Batten BBDF Neurofilaments
BRIEF

published on 06/06/2024 at 07:35, 2 years ago

Theranexus and BBDF Announce Positive Results at 18 Months for Batten-1 in Phase 1/2 Study

Theranexus Batten-1 BBDF Batten Disease Neurofilaments
PRESS RELEASE

published on 06/06/2024 at 07:30, 2 years ago

Theranexus et BBDF confirment les résultats positifs à 18 mois de Batten-1 dans l'étude de phase 1/2 sur les neurofilaments, un biomarqueur de la mort neuronale
Theranexus et BBDF confirment les résultats positifs à 18 mois de l'étude de phase 1/2 sur les neurofilaments, biomarqueur de la mort neuronale, concernant le médicament Batten-1 dans la maladie de Batten (CLN3)

Theranexus Batten-1 Maladie De Batten BBDF Neurofilaments
PRESS RELEASE

published on 06/06/2024 at 07:30, 2 years ago

Theranexus and BBDF confirm positive 18-month results for Batten-1 in Phase I/II trial based on neurofilaments, a biomarker of neuronal death
Theranexus and BBDF confirm positive results in Phase I/II trial evaluating Batten-1 drug for CLN3 Batten disease after 18 months of treatment, showing decline in NfL biomarker levels and therapeutic potential

Theranexus Batten-1 BBDF CLN3 Batten Disease Neurofilament Light Chains
BRIEF

published on 05/02/2024 at 07:35, 2 years 1 month ago

Theranexus dévoile son document d'enregistrement universel pour 2023

2023 Biopharmaceutique Document D'Enregistrement Universel Theranexus Maladies Neurologiques Rares
BRIEF

published on 05/02/2024 at 07:35, 2 years 1 month ago

Theranexus unveils its universal registration document for 2023

2023 Biopharmaceutical Universal Registration Document Theranexus Rare Neurological Diseases
PRESS RELEASE

published on 05/02/2024 at 07:30, 2 years 1 month ago

MISE A DISPOSITION DU DOCUMENT D'ENREGISTREMENT UNIVERSEL 2023
Theranexus annonce le dépôt de son document d'enregistrement universel pour l'exercice 2023, disponible sur son site. Theranexus se spécialise dans le traitement des maladies neurologiques rares

Biopharmaceutique Theranexus Maladies Neurologiques Rares Dépôt Document D'enregistrement Universel Neurones Et Cellules Gliales
BRIEF

published on 04/29/2024 at 18:25, 2 years 1 month ago

Theranexus Reports 2023 Full-Year Results and Details Recent Progress

2023 Financial Results Theranexus Rare Neurological Diseases PickASO Project Batten Disease
BRIEF

published on 04/29/2024 at 18:25, 2 years 1 month ago

Theranexus publie ses résultats annuels 2023 et détaille ses progrès récents

Résultats Financiers 2023 Theranexus Maladies Neurologiques Rares Maladie Des Lattes Projet PickASO

Accesswire

Published on 06/22/2026 at 03:00, 4 hours 1 minute ago

Tunkillia Pre-Feasibility Study Begins
Published on 06/20/2026 at 01:00, 2 days 6 hours ago

Onco-Innovations Announces Non-Brokered LIFE Offering
Published on 06/20/2026 at 00:00, 2 days 7 hours ago

Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Published on 06/19/2026 at 04:30, 3 days 2 hours ago

Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 3 days 5 hours ago

American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting

View all ACCESSWIRE

EQS Group

Published on 06/22/2026 at 06:05, 56 minutes ago

adidas and GLO Brands B.V., debuts ADIDAS PRO WORK, a new safety footwear range, combining performance, protection and style for the modern worksite
Published on 06/22/2026 at 04:05, 2 hours 56 minutes ago

Optro Accelerates Global Growth with Singapore Hub, Delivering Agentic GRC to APAC Enterprises
Published on 06/20/2026 at 21:25, 1 day 9 hours ago

VIVATECH 2026 CELEBRATES ITS 10TH ANNIVERSARY WITH A RECORD EDITION SURPASSING 200,000 VISITORS
Published on 06/20/2026 at 06:00, 2 days 1 hour ago

Successful debut of International Symposium on Emergency Response and Aeromedical Services in Hong Kong
Published on 06/19/2026 at 20:17, 2 days 10 hours ago

2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations

Les Echos

Published on 06/19/2026 at 19:33, 2 days 11 hours ago

Déclaration hebdomadaire d'opérations effectuées du 15 au 19 juin 2026
Published on 06/19/2026 at 19:33, 2 days 11 hours ago

Disclosure of transactions in own shares from June 15 to June 19, 2026
Published on 06/19/2026 at 19:23, 2 days 11 hours ago

Imerys-06-2026-communique-capital-droits-de-vote-au-31-mai-2026
Published on 06/19/2026 at 19:23, 2 days 11 hours ago

Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026
Published on 06/19/2026 at 19:05, 2 days 11 hours ago

CP - Changement de gouvernance

View all LES ECHOS COMFI WIRE